Biogen (BIIB) Competitors

$191.91 -1.04 (-0.54%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$192.00 +0.09 (+0.05%)

As of 05/18/2026 07:37 PM Eastern

BIIB vs. AMGN, GILD, IONS, MRNA, and PRTA

Should you buy Biogen stock or one of its competitors? MarketBeat compares Biogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biogen include Amgen (AMGN), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), Moderna (MRNA), and Prothena (PRTA). These companies are all part of the "medical" sector.

How does Biogen compare to Amgen?

Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Amgen has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$36.75B	4.76	$7.71B	$14.37	22.57
Biogen	$9.89B	2.86	$1.29B	$9.32	20.59

Amgen presently has a consensus price target of $356.15, suggesting a potential upside of 9.79%. Biogen has a consensus price target of $215.62, suggesting a potential upside of 12.35%. Given Biogen's stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.48
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52

In the previous week, Biogen had 10 more articles in the media than Amgen. MarketBeat recorded 52 mentions for Biogen and 42 mentions for Amgen. Amgen's average media sentiment score of 1.10 beat Biogen's score of 0.84 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	25 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Positive
Biogen	20 Very Positive mention(s)	15 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Amgen has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Biogen has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Amgen has a net margin of 20.96% compared to Biogen's net margin of 13.81%. Amgen's return on equity of 137.41% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	20.96%	137.41%	13.28%
Biogen	13.81%	12.83%	8.01%

76.5% of Amgen shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.9% of Amgen shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Amgen beats Biogen on 12 of the 17 factors compared between the two stocks.

How does Biogen compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Biogen has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

In the previous week, Biogen had 11 more articles in the media than Gilead Sciences. MarketBeat recorded 52 mentions for Biogen and 41 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.87 beat Biogen's score of 0.84 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	24 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive
Biogen	20 Very Positive mention(s)	15 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	5.47	$8.51B	$7.34	17.67
Biogen	$9.89B	2.86	$1.29B	$9.32	20.59

Gilead Sciences has a net margin of 30.99% compared to Biogen's net margin of 13.81%. Gilead Sciences' return on equity of 48.19% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	30.99%	48.19%	18.28%
Biogen	13.81%	12.83%	8.01%

Gilead Sciences presently has a consensus target price of $157.04, indicating a potential upside of 21.11%. Biogen has a consensus target price of $215.62, indicating a potential upside of 12.35%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.86
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52

Summary

Gilead Sciences beats Biogen on 12 of the 17 factors compared between the two stocks.

How does Biogen compare to Ionis Pharmaceuticals?

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Biogen presently has a consensus price target of $215.62, suggesting a potential upside of 12.35%. Ionis Pharmaceuticals has a consensus price target of $99.35, suggesting a potential upside of 37.00%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Biogen had 45 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 52 mentions for Biogen and 7 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.96 beat Biogen's score of 0.84 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	20 Very Positive mention(s)	15 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.86	$1.29B	$9.32	20.59
Ionis Pharmaceuticals	$944M	12.70	-$381.39M	-$2.07	N/A

Biogen has a net margin of 13.81% compared to Ionis Pharmaceuticals' net margin of -30.91%. Biogen's return on equity of 12.83% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%

87.9% of Biogen shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Biogen and Ionis Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Biogen compare to Moderna?

Biogen (NASDAQ:BIIB) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	2.86	$1.29B	$9.32	20.59
Moderna	$1.94B	9.82	-$2.82B	-$8.15	N/A

In the previous week, Biogen had 39 more articles in the media than Moderna. MarketBeat recorded 52 mentions for Biogen and 13 mentions for Moderna. Biogen's average media sentiment score of 0.84 beat Moderna's score of 0.71 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	20 Very Positive mention(s)	15 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Moderna	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Biogen has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Biogen currently has a consensus target price of $215.62, suggesting a potential upside of 12.35%. Moderna has a consensus target price of $35.73, suggesting a potential downside of 25.73%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Biogen has a net margin of 13.81% compared to Moderna's net margin of -143.55%. Biogen's return on equity of 12.83% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Moderna	-143.55%	-26.64%	-19.32%

Summary

Biogen beats Moderna on 14 of the 17 factors compared between the two stocks.

How does Biogen compare to Prothena?

Prothena (NASDAQ:PRTA) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

In the previous week, Biogen had 40 more articles in the media than Prothena. MarketBeat recorded 52 mentions for Biogen and 12 mentions for Prothena. Biogen's average media sentiment score of 0.84 beat Prothena's score of -0.47 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	20 Very Positive mention(s)	15 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Prothena currently has a consensus price target of $21.78, suggesting a potential upside of 127.09%. Biogen has a consensus price target of $215.62, suggesting a potential upside of 12.35%. Given Prothena's higher probable upside, equities analysts plainly believe Prothena is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prothena	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52

97.1% of Prothena shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Prothena has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market. Comparatively, Biogen has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market.

Biogen has a net margin of 13.81% compared to Prothena's net margin of -260.92%. Biogen's return on equity of 12.83% beat Prothena's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prothena	-260.92%	-43.44%	-36.87%
Biogen	13.81%	12.83%	8.01%

Biogen has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prothena	$9.68M	51.86	-$244.09M	-$2.82	N/A
Biogen	$9.89B	2.86	$1.29B	$9.32	20.59

Summary

Biogen beats Prothena on 12 of the 16 factors compared between the two stocks.

Get Biogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIIB vs. The Competition

Export

Metric	Biogen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.49B	$3.31B	$6.25B	$12.29B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	20.59	18.13	20.86	25.23
Price / Sales	2.86	274.73	549.93	74.46
Price / Cash	8.52	55.27	27.48	37.30
Price / Book	1.54	6.57	9.67	6.63
Net Income	$1.29B	$24.35M	$3.56B	$335.59M
7 Day Performance	-3.74%	-2.53%	-1.70%	-1.20%
1 Month Performance	8.21%	-3.55%	-2.66%	-1.16%
1 Year Performance	48.26%	53.51%	30.03%	28.10%

Biogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIIB Biogen	4.061 of 5 stars	$191.91 -0.5%	$215.62 +12.4%	+52.8%	$28.49B	$9.89B	20.59	7,500
AMGN Amgen	4.1143 of 5 stars	$329.59 -0.6%	$357.12 +8.4%	+19.1%	$177.87B	$37.22B	22.94	31,500	Positive News
GILD Gilead Sciences	4.7853 of 5 stars	$133.52 +1.7%	$157.04 +17.6%	+26.5%	$165.73B	$29.74B	18.19	17,000	Insider Trade Analyst Revision
IONS Ionis Pharmaceuticals	3.2109 of 5 stars	$75.38 -0.4%	$99.35 +31.8%	+116.1%	$12.46B	$944M	N/A	1,402	Analyst Forecast
MRNA Moderna	1.6109 of 5 stars	$52.88 -2.7%	$35.73 -32.4%	+93.5%	$20.98B	$2.20B	N/A	4,700	Insider Trade Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIIB) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Competitors